Mary T. Szela

Chief Executive Officer & President at TriSalus Life Sciences

Mary T. Szela

Mary T. Szela

Chief Executive Officer & President at TriSalus Life Sciences

Overview
Career Highlights

TriSalus Life Sciences
Novelion Therapeutics, Inc.
Aegerion Pharmaceuticals Inc.

RelSci Relationships

1725

Number of Boards

17

Birthday

1964

Age

56

Contact Data
Trying to get in touch with Mary T. Szela? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Mary T. Szela likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Celldex Therapeutics Inc.

Relationship likelihood: Strong

Associate Director of Product Development at Institute of Molecular Biology, Inc.

Relationship likelihood: Strong

Executive Chairman at KMG Capital Partners LLC

Relationship likelihood: Strong

Executive Director at Vatera Healthcare Partners

Relationship likelihood: Strong

Founder at Healthquest Capital Management Co LLC

Relationship likelihood: Strong

Operating Partner at Shore Capital Partners LLC

Relationship likelihood: Strong

President, Chief Executive Officer & Chairman at Coherus BioSciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Chief Investment Officer at Vatera Healthcare Partners

Relationship likelihood: Strong

Former President & Chief Executive Officer at Chiasma, Inc.

Relationship likelihood: Strong

Chief Scientific Officer, Executive Vice President & Co-Founder at Arisaph Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Mary T. Szela
Potential Connections via
Relationship Science
You
Mary T. Szela
Chief Executive Officer & President at TriSalus Life Sciences
Career History
Chief Executive Officer & President
2018 - Current

Surefire Medical, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Director & Chief Executive Officer
2016 - 2017

Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and is headquartered in Vancouver, Canada.

Chief Executive Officer
2016 - 2017

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA.

Boards & Committees
Member, Board of Directors
Current
Transactions
Details Hidden

Abbott Laboratories raised money in a private placement transaction

Details Hidden

Abbott Laboratories raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mary T. Szela. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mary T. Szela's profile does not indicate a business or promotional relationship of any kind between RelSci and Mary T. Szela.